{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:10:13Z","timestamp":1793707813052,"version":"4.6.1"},"reference-count":221,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.rmed.2018.12.015","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T11:32:57Z","timestamp":1547033577000},"page":"79-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":481,"special_numbering":"C","title":["Inflammation and immunity in IPF pathogenesis and treatment"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-5273","authenticated-orcid":false,"given":"P.","family":"Heukels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.C.","family":"Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib2","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"124","key":"10.1016\/j.rmed.2018.12.015_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1183\/09059180.00000812","article-title":"An earlier and more confident diagnosis of idiopathic pulmonary fibrosis","volume":"21","author":"du Bois","year":"2012","journal-title":"Eur. Respir. Rev."},{"issue":"22","key":"10.1016\/j.rmed.2018.12.015_bib4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.rmed.2018.12.015_bib5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2169\/internalmedicine.55.5272","article-title":"Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis","volume":"55","author":"Bando","year":"2016","journal-title":"Intern. Med."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/thoraxjnl-2015-207011","article-title":"Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis","volume":"71","author":"Nathan","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2018.12.015_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir. Med."},{"issue":"9842","key":"10.1016\/j.rmed.2018.12.015_bib9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(12)61144-1","article-title":"New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis","volume":"380","author":"Fernandez","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.rmed.2018.12.015_bib10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1084\/jem.20110551","article-title":"Integrating mechanisms of pulmonary fibrosis","volume":"208","author":"Wynn","year":"2011","journal-title":"J. Exp. Med."},{"issue":"9842","key":"10.1016\/j.rmed.2018.12.015_bib11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","article-title":"Interstitial lung disease in connective tissue disorders","volume":"380","author":"Fischer","year":"2012","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.rmed.2018.12.015_bib12","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.rmed.2018.12.015_bib14","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/thoraxjnl-2016-209172","article-title":"Pulmonary fibrosis in the era of stratified medicine","volume":"71","author":"Mathai","year":"2016","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.rmed.2018.12.015_bib15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/jmg.2008.057356","article-title":"A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis","volume":"45","author":"Mushiroda","year":"2008","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1165\/rcmb.2008-0485TR","article-title":"WNT signaling in lung disease: a failure or a regeneration signal?","volume":"42","author":"Konigshoff","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1164\/rccm.201202-0282PP","article-title":"Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis","volume":"186","author":"Faner","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-2600(13)70045-6","article-title":"Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study","volume":"1","author":"Noth","year":"2013","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14728222.2014.988706","article-title":"Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis","volume":"19","author":"O'Dwyer","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12863-016-0377-2","article-title":"Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia","volume":"17","author":"Fingerlin","year":"2016","journal-title":"BMC Genet."},{"issue":"7501","key":"10.1016\/j.rmed.2018.12.015_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature13193","article-title":"The role of senescent cells in ageing","volume":"509","author":"van Deursen","year":"2014","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.rmed.2018.12.015_bib22","doi-asserted-by":"crossref","first-page":"13051","DOI":"10.1073\/pnas.0804280105","article-title":"Short telomeres are a risk factor for idiopathic pulmonary fibrosis","volume":"105","author":"Alder","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.rmed.2018.12.015_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189467","article-title":"Short telomere length in IPF lung associates with fibrotic lesions and predicts survival","volume":"12","author":"Snetselaar","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2018.12.015_bib24","first-page":"CD002880","article-title":"Corticosteroids for idiopathic pulmonary fibrosis","volume":"3","author":"Richeldi","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"21","key":"10.1016\/j.rmed.2018.12.015_bib25","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Idiopathic Pulmonary Fibrosis Clinical Research","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9685","key":"10.1016\/j.rmed.2018.12.015_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","article-title":"Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial","volume":"374","author":"King","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa030511","article-title":"A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis","volume":"350","author":"Raghu","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-2600(16)30421-0","article-title":"Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial","volume":"5","author":"Raghu","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.rmed.2018.12.015_bib29","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1164\/rccm.200709-1446OC","article-title":"Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial","volume":"178","author":"Raghu","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib30","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.intimp.2013.06.034","article-title":"Neutrophil cell surface receptors and their intracellular signal transduction pathways","volume":"17","author":"Futosi","year":"2013","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.rmed.2018.12.015_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-020712-164023","article-title":"The multifaceted functions of neutrophils","volume":"9","author":"Mayadas","year":"2014","journal-title":"Annu. Rev. Pathol."},{"issue":"11","key":"10.1016\/j.rmed.2018.12.015_bib32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/thx.54.11.1015","article-title":"Granulocyte-colony stimulating factor levels in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis","volume":"54","author":"Ashitani","year":"1999","journal-title":"Thorax"},{"issue":"3 Pt 1","key":"10.1016\/j.rmed.2018.12.015_bib33","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1164\/ajrccm.149.3.8118632","article-title":"Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis","volume":"149","author":"Car","year":"1994","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171344","article-title":"Sputum biomarkers in IPF: evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7","volume":"12","author":"Guiot","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2018.12.015_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cyto.2016.12.008","article-title":"Glycosaminoglycans are important mediators of neutrophilic inflammation in vivo","volume":"91","author":"Gschwandtner","year":"2017","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.03.00105202","article-title":"BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia","volume":"22","author":"Veeraraghavan","year":"2003","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/MCP.0b013e328349ac2b","article-title":"Modeling pulmonary fibrosis with bleomycin","volume":"17","author":"Mouratis","year":"2011","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1189\/jlb.3HI1014-493R","article-title":"Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis","volume":"98","author":"Gregory","year":"2015","journal-title":"J. Leukoc. Biol."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib39","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1183\/09031936.00127011","article-title":"A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice","volume":"40","author":"Takemasa","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nri978","article-title":"Alternative activation of macrophages","volume":"3","author":"Gordon","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"7446","key":"10.1016\/j.rmed.2018.12.015_bib41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.immuni.2010.05.007","article-title":"Alternative activation of macrophages: mechanism and functions","volume":"32","author":"Gordon","year":"2010","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib43","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1615\/CritRevImmunol.v32.i6.10","article-title":"M1 and M2 macrophages: oracles of health and disease","volume":"32","author":"Mills","year":"2012","journal-title":"Crit. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v7.i4.231","article-title":"Mechanisms of the alternative activation of macrophages and non-coding RNAs in the development of radiation-induced lung fibrosis","volume":"7","author":"Duru","year":"2016","journal-title":"World J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00408-009-9223-x","article-title":"Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis","volume":"188","author":"Ando","year":"2010","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116775","article-title":"Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Schupp","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2018.12.015_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2018.01.023","article-title":"CCL18 - beyond chemotaxis","volume":"109","author":"Chenivesse","year":"2018","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.rmed.2018.12.015_bib48","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.rmed.2013.06.004","article-title":"CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases","volume":"107","author":"Cai","year":"2013","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2018.12.015_bib49","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1164\/rccm.200509-1518OC","article-title":"A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18","volume":"173","author":"Prasse","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.rmed.2018.12.015_bib50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbadis.2012.12.001","article-title":"Macrophages and fibrosis: how resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair","volume":"1832","author":"Lech","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib51","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1165\/rcmb.2015-0020TR","article-title":"Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis","volume":"53","author":"Craig","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0046-8177(94)90117-1","article-title":"Monocyte chemoattractant protein-1 in idiopathic pulmonary fibrosis and other interstitial lung diseases","volume":"25","author":"Iyonaga","year":"1994","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib54","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1034\/j.1399-3003.1999.14b23.x","article-title":"Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases","volume":"14","author":"Suga","year":"1999","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib55","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1183\/13993003.01558-2014","article-title":"CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.rmed.2018.12.015_bib56","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nri1733","article-title":"Monocyte and macrophage heterogeneity","volume":"5","author":"Gordon","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.rmed.2018.12.015_bib57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fimmu.2013.00023","article-title":"Toward a refined definition of monocyte subsets","volume":"4","author":"Ziegler-Heitbrock","year":"2013","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib58","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nri3671","article-title":"Monocytes and macrophages: developmental pathways and tissue homeostasis","volume":"14","author":"Ginhoux","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"56","key":"10.1016\/j.rmed.2018.12.015_bib59","article-title":"Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis","volume":"1","author":"Moore","year":"2014","journal-title":"Front. Med."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011049","article-title":"Functional contribution of elevated circulating and hepatic non-classical CD14(+)CD16(+) monocytes to inflammation and human liver fibrosis","volume":"5","author":"Zimmermann","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib61","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.4049\/jimmunol.178.4.2000","article-title":"Distinct differentiation potential of blood monocyte subsets in the lung","volume":"178","author":"Landsman","year":"2007","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib62","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/labinvest.2010.73","article-title":"Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype","volume":"90","author":"Mathai","year":"2010","journal-title":"Lab. Invest."},{"key":"10.1016\/j.rmed.2018.12.015_bib63","doi-asserted-by":"crossref","first-page":"703653","DOI":"10.1155\/2014\/703653","article-title":"Monocyte subsets in schistosomiasis patients with periportal fibrosis","volume":"2014","author":"Fernandes","year":"2014","journal-title":"Mediat. Inflamm."},{"issue":"7","key":"10.1016\/j.rmed.2018.12.015_bib64","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s10067-017-3597-6","article-title":"CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis","volume":"36","author":"Lescoat","year":"2017","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib65","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.4049\/jimmunol.1400281","article-title":"Distinct Fcgamma receptors mediate the effect of serum amyloid p on neutrophil adhesion and fibrocyte differentiation","volume":"193","author":"Cox","year":"2014","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib66","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF03403533","article-title":"Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair","volume":"1","author":"Bucala","year":"1994","journal-title":"Mol. Med."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nri2990","article-title":"Fibrocytes: emerging effector cells in chronic inflammation","volume":"11","author":"Reilkoff","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib68","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/stem.1648","article-title":"Tracking the elusive fibrocyte: identification and characterization of collagen-producing hematopoietic lineage cells during murine wound healing","volume":"32","author":"Suga","year":"2014","journal-title":"Stem Cell."},{"issue":"10","key":"10.1016\/j.rmed.2018.12.015_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007475","article-title":"Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts","volume":"4","author":"Pilling","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib70","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000369714","article-title":"Curcumin treatment suppresses CCR7 expression and the differentiation and migration of human circulating fibrocytes","volume":"35","author":"Fu","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"issue":"9","key":"10.1016\/j.rmed.2018.12.015_bib71","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/all.12444","article-title":"CCL2 release by airway smooth muscle is increased in asthma and promotes fibrocyte migration","volume":"69","author":"Singh","year":"2014","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.rmed.2018.12.015_bib72","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.biocel.2008.02.012","article-title":"Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis","volume":"40","author":"Andersson-Sjoland","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib73","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4049\/jimmunol.160.1.419","article-title":"Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes","volume":"160","author":"Chesney","year":"1998","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib74","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biocel.2003.10.005","article-title":"Circulating fibrocytes: collagen-secreting cells of the peripheral blood","volume":"36","author":"Quan","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib75","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4049\/jimmunol.160.1.419","article-title":"Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes","volume":"160","author":"Chesney","year":"1998","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib76","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1165\/rcmb.2013-0042OC","article-title":"Bone marrow-derived stromal cells are invasive and hyperproliferative and alter transforming growth factor-alpha-induced pulmonary fibrosis","volume":"50","author":"Madala","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib77","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1164\/rccm.201407-1334OC","article-title":"Fibrocytes contribute to inflammation and fibrosis in chronic hypersensitivity pneumonitis through paracrine effects","volume":"191","author":"Garcia de Alba","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib78","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1172\/JCI200420997","article-title":"Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis","volume":"114","author":"Phillips","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.rmed.2018.12.015_bib79","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1164\/rccm.200810-1534OC","article-title":"Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis","volume":"179","author":"Moeller","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib80","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1440-1843.2012.02167.x","article-title":"Correlation between circulating fibrocytes, and activity and progression of interstitial lung diseases","volume":"17","author":"Fujiwara","year":"2012","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib81","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12931-017-0623-9","article-title":"Fibrocyte measurement in peripheral blood correlates with number of cultured mature fibrocytes in vitro and is a potential biomarker for interstitial lung disease in Rheumatoid Arthritis","volume":"18","author":"Just","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2018.12.015_bib82","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbacli.2014.06.002","article-title":"Enumeration of circulating fibrocytes for clinical use in asthma by an optimized single-platform flow cytometry assay","volume":"1","author":"Bianchetti","year":"2014","journal-title":"BBA Clin."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib83","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12931-018-0798-8","article-title":"Fibrocytes are increased in lung and peripheral blood of patients with idiopathic pulmonary fibrosis","volume":"19","author":"Heukels","year":"2018","journal-title":"Respir. Res."},{"issue":"11","key":"10.1016\/j.rmed.2018.12.015_bib84","first-page":"1229","article-title":"Targeting Th2 cytokines in fibrotic diseases","volume":"11","author":"Morishima","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000073718","article-title":"Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro","volume":"132","author":"Saito","year":"2003","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"8","key":"10.1016\/j.rmed.2018.12.015_bib86","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","article-title":"Fibrotic disease and the T(H)1\/T(H)2 paradigm","volume":"4","author":"Wynn","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib87","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.arcmed.2008.02.005","article-title":"TH1\/TH2 immune response in lung fibroblasts in interstitial lung disease","volume":"39","author":"Sumida","year":"2008","journal-title":"Arch. Med. Res."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib88","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.it.2009.12.001","article-title":"The immunology of fibrosis: innate and adaptive responses","volume":"31","author":"Wick","year":"2010","journal-title":"Trends Immunol."},{"key":"10.1016\/j.rmed.2018.12.015_bib89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-immunol-032712-095937","article-title":"The immunology of fibrosis","volume":"31","author":"Wick","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/mi.2008.85","article-title":"Pulmonary fibrosis: pathogenesis, etiology and regulation","volume":"2","author":"Wilson","year":"2009","journal-title":"Mucosal Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib91","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.rmed.2018.12.015_bib92","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1146\/annurev-immunol-020711-075053","article-title":"Innate lymphoid cells: emerging insights in development, lineage relationships, and function","volume":"30","author":"Spits","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.rmed.2018.12.015_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2016.01.018","article-title":"Regulation of group 2 innate lymphoid cells","volume":"87","author":"Duerr","year":"2016","journal-title":"Cytokine"},{"issue":"10","key":"10.1016\/j.rmed.2018.12.015_bib94","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.4049\/jimmunol.0903818","article-title":"IL-33 mediates inflammatory responses in human lung tissue cells","volume":"185","author":"Yagami","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.rmed.2018.12.015_bib95","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.imlet.2017.08.022","article-title":"Innate lymphoid cells and fibrotic regulation","volume":"195","author":"Horsburgh","year":"2018","journal-title":"Immunol. Lett."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib96","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jaci.2014.05.011","article-title":"IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice","volume":"134","author":"Li","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib97","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1073\/pnas.1315854111","article-title":"IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis","volume":"111","author":"Hams","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib98","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.immuni.2013.07.018","article-title":"Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis","volume":"39","author":"McHedlidze","year":"2013","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.rmed.2018.12.015_bib99","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1002\/art.11089","article-title":"Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts","volume":"48","author":"McGaha","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib100","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1084\/jem.194.6.809","article-title":"Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)","volume":"194","author":"Lee","year":"2001","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib101","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2047-1440-2-16","article-title":"IL-13 signaling via IL-13Ralpha2 triggers TGF-beta1-dependent allograft fibrosis","volume":"2","author":"Brunner","year":"2013","journal-title":"Transplant. Res."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib102","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02111-2018","article-title":"Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end","volume":"52","author":"Wijsenbeek","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib103","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/annrheumdis-2015-207388","article-title":"Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis","volume":"75","author":"Wohlfahrt","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.rmed.2018.12.015_bib104","doi-asserted-by":"crossref","first-page":"14017","DOI":"10.1038\/ncomms14017","article-title":"A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis","volume":"8","author":"Moretti","year":"2017","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.rmed.2018.12.015_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188649","article-title":"Human intrahepatic ILC2 are IL-13positive amphiregulinpositive and their frequency correlates with model of end stage liver disease score","volume":"12","author":"Jeffery","year":"2017","journal-title":"PLoS One"},{"issue":"50","key":"10.1016\/j.rmed.2018.12.015_bib106","doi-asserted-by":"crossref","first-page":"41991","DOI":"10.1074\/jbc.M112.356824","article-title":"Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-beta-induced pulmonary fibrosis","volume":"287","author":"Zhou","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib107","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nri2782","article-title":"Mast cell-orchestrated immunity to pathogens","volume":"10","author":"Abraham","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib108","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/dna.2013.2005","article-title":"Mast cells: a pivotal role in pulmonary fibrosis","volume":"32","author":"Veerappan","year":"2013","journal-title":"DNA Cell Biol."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib109","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1042\/cs0810183","article-title":"Mast cell tryptase and histamine concentrations in bronchoalveolar lavage fluid from patients with interstitial lung disease","volume":"81","author":"Walls","year":"1991","journal-title":"Clin. Sci. (Lond.)"},{"issue":"12","key":"10.1016\/j.rmed.2018.12.015_bib110","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1164\/rccm.201009-1479OC","article-title":"Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis","volume":"183","author":"Wygrecka","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.rmed.2018.12.015_bib111","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/thx.43.7.552","article-title":"Effect of histamine on proliferation of normal human adult lung fibroblasts","volume":"43","author":"Jordana","year":"1988","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib112","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.4049\/jimmunol.158.5.2310","article-title":"Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis","volume":"158","author":"Gruber","year":"1997","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib113","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1164\/rccm.200410-1384SO","article-title":"Pulmonary dendritic cells","volume":"172","author":"Vermaelen","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.12.015_bib114","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1165\/rcmb.2017-0051PS","article-title":"Dendritic cell trafficking and function in rare lung diseases","volume":"57","author":"Liu","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"10","key":"10.1016\/j.rmed.2018.12.015_bib116","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.4049\/jimmunol.176.10.5735","article-title":"Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis","volume":"176","author":"Marchal-Somme","year":"2006","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.rmed.2018.12.015_bib117","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1084\/jem.20090410","article-title":"Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice","volume":"206","author":"GeurtsvanKessel","year":"2009","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib118","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/imm.12554","article-title":"Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues","volume":"147","author":"Jones","year":"2016","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib119","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/modpathol.2011.166","article-title":"The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis","volume":"25","author":"Nuovo","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.rmed.2018.12.015_bib120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JIR.S40673","article-title":"Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis","volume":"6","author":"Todd","year":"2013","journal-title":"J. Inflamm. Res."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib121","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1165\/rcmb.2017-0051PS","article-title":"Dendritic cell trafficking and function in rare lung diseases","volume":"57","author":"Liu","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib122","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000226244","article-title":"Increased bronchoalveolar lavage fluid CD1c expressing dendritic cells in idiopathic pulmonary fibrosis","volume":"78","author":"Tsoumakidou","year":"2009","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2018.12.015_bib123","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-016-0345-4","article-title":"Human lung fibroblasts may modulate dendritic cell phenotype and function: results from a pilot in vitro study","volume":"17","author":"Freynet","year":"2016","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib124","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1164\/rccm.200907-1164OC","article-title":"A role for dendritic cells in bleomycin-induced pulmonary fibrosis in mice?","volume":"182","author":"Bantsimba-Malanda","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib125","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1164\/arrd.1983.127.5.614","article-title":"The effects of the nude (nu\/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation","volume":"127","author":"Schrier","year":"1983","journal-title":"Am. Rev. Respir. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib126","doi-asserted-by":"crossref","first-page":"L92","DOI":"10.1152\/ajplung.2001.281.1.L92","article-title":"IL-12 attenuates bleomycin-induced pulmonary fibrosis","volume":"281","author":"Keane","year":"2001","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib127","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/pmic.200301007","article-title":"Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis","volume":"5","author":"Rottoli","year":"2005","journal-title":"Proteomics"},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nri.2017.118","article-title":"TH2 cell development and function","volume":"18","author":"Walker","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1081-1206(10)62426-X","article-title":"T-cell subsets (Th1 versus Th2)","volume":"85","author":"Romagnani","year":"2000","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.12.015_bib130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-immunol-032712-095937","article-title":"The immunology of fibrosis","volume":"31","author":"Wick","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib131","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1165\/rcmb.2016-0121TR","article-title":"Immune mechanisms in pulmonary fibrosis","volume":"55","author":"Kolahian","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib132","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.aller.2018.02.003","article-title":"Features and roles of T helper 9 cells and interleukin 9 in immunological diseases","volume":"47","author":"Yazdani","year":"2019","journal-title":"Allergol. Immunopathol."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib133","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2013.10.004","article-title":"Th9 cells, new players in adaptive immunity","volume":"35","author":"Schmitt","year":"2014","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib134","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri3824","article-title":"The development and in vivo function of T helper 9 cells","volume":"15","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib135","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.4049\/jimmunol.1003049","article-title":"A brief history of IL-9","volume":"186","author":"Goswami","year":"2011","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib136","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1165\/ajrcmb.24.4.4249","article-title":"Interleukin-9 reduces lung fibrosis and type 2 immune polarization induced by silica particles in a murine model","volume":"24","author":"Arras","year":"2001","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib137","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0002-9440(10)62236-5","article-title":"IL-9 protects against bleomycin-induced lung injury: involvement of prostaglandins","volume":"166","author":"Arras","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.rmed.2018.12.015_bib138","doi-asserted-by":"crossref","first-page":"18694","DOI":"10.1038\/srep18694","article-title":"A deleterious role for Th9\/IL-9 in hepatic fibrogenesis","volume":"6","author":"Qin","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib139","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1165\/rcmb.2006-0397OC","article-title":"Profibrotic effect of IL-9 overexpression in a model of airway remodeling","volume":"37","author":"van den Brule","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.rmed.2018.12.015_bib140","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib141","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00017-2018","article-title":"Analysis of pulmonary features and treatment approaches in the COPA syndrome","volume":"4","author":"Tsui","year":"2018","journal-title":"ERJ Open Res."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib142","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ng.3279","article-title":"COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis","volume":"47","author":"Watkin","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.rmed.2018.12.015_bib143","first-page":"14","article-title":"Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis","volume":"34","author":"Lei","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib144","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/01902148.2013.872210","article-title":"Interleukin-17A antagonist attenuates radiation-induced lung injuries in mice","volume":"40","author":"Wang","year":"2014","journal-title":"Exp. Lung Res."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib145","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.rmed.2018.12.015_bib146","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20070663","article-title":"Phenotypic and functional features of human Th17 cells","volume":"204","author":"Annunziato","year":"2007","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib147","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.taap.2013.11.012","article-title":"Neutralization of interleukin-17A delays progression of silica-induced lung inflammation and fibrosis in C57BL\/6 mice","volume":"275","author":"Chen","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib148","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4049\/jimmunol.182.1.657","article-title":"Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis","volume":"182","author":"Simonian","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.rmed.2018.12.015_bib149","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12890-015-0012-4","article-title":"IL-27 alleviates the bleomycin-induced pulmonary fibrosis by regulating the Th17 cell differentiation","volume":"15","author":"Dong","year":"2015","journal-title":"BMC Pulm. Med."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib150","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.4049\/jimmunol.0900568","article-title":"IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells","volume":"183","author":"Murugaiyan","year":"2009","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.rmed.2018.12.015_bib151","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.4049\/jimmunol.0900459","article-title":"IL-17A-producing gammadelta T and Th17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis","volume":"184","author":"Lo Re","year":"2010","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.rmed.2018.12.015_bib152","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.4049\/jimmunol.1100591","article-title":"Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts","volume":"188","author":"Nakashima","year":"2012","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.rmed.2018.12.015_bib153","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.rmed.2018.12.015_bib154","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1164\/rccm.201103-0516OC","article-title":"Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis","volume":"184","author":"Lo Re","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.rmed.2018.12.015_bib155","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1164\/rccm.200812-1936OC","article-title":"Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis","volume":"179","author":"Kotsianidis","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.12.015_bib156","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fphar.2014.00080","article-title":"CD4+CD25+FoxP3+ Regulatory Tregs inhibit fibrocyte recruitment and fibrosis via suppression of FGF-9 production in the TGF-beta1 exposed murine lung","volume":"5","author":"Peng","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.rmed.2018.12.015_bib157","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.ajpath.2016.03.020","article-title":"CD4(+)CD25(hi)Foxp3(+) cells exacerbate bleomycin-induced pulmonary fibrosis","volume":"186","author":"Birjandi","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib158","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12931-017-0653-3","article-title":"Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis","volume":"18","author":"Hou","year":"2017","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib159","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.imbio.2012.05.020","article-title":"Differential role of regulatory T cells in early and late stages of pulmonary fibrosis","volume":"218","author":"Boveda-Ruiz","year":"2013","journal-title":"Immunobiology"},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib160","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.201206-1109OC","article-title":"Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-beta1-induced pulmonary fibrosis","volume":"187","author":"Reilkoff","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.rmed.2018.12.015_bib161","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1164\/rccm.201611-2263OC","article-title":"Deep proteome profiling reveals common prevalence of MZB1-positive plasma B cells in human lung and skin fibrosis","volume":"196","author":"Schiller","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib162","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/thoraxjnl-2013-204596","article-title":"Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis","volume":"70","author":"DePianto","year":"2015","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.rmed.2018.12.015_bib163","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1073\/pnas.1520112113","article-title":"CXCL13 is a plasma biomarker of germinal center activity","volume":"113","author":"Havenar-Daughton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.rmed.2018.12.015_bib164","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1164\/rccm.201309-1592OC","article-title":"C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis","volume":"189","author":"Vuga","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib166","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4049\/jimmunol.1203476","article-title":"Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients","volume":"191","author":"Xue","year":"2013","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib167","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"issue":"4\u20135","key":"10.1016\/j.rmed.2018.12.015_bib168","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.humimm.2006.02.026","article-title":"Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies","volume":"67","author":"Magro","year":"2006","journal-title":"Hum. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib169","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s004080000020","article-title":"Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis","volume":"178","author":"Dobashi","year":"2000","journal-title":"Lung"},{"issue":"3\u20134","key":"10.1016\/j.rmed.2018.12.015_bib170","first-page":"181","article-title":"Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis","volume":"48","author":"Ogushi","year":"2001","journal-title":"J. Med. Invest."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib171","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4049\/jimmunol.181.1.756","article-title":"Identification of annexin 1 as a novel autoantigen in acute exacerbation of idiopathic pulmonary fibrosis","volume":"181","author":"Kurosu","year":"2008","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib172","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1164\/rccm.201001-0076OC","article-title":"Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis","volume":"183","author":"Taille","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.rmed.2018.12.015_bib173","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1164\/rccm.201203-0506OC","article-title":"Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses","volume":"187","author":"Kahloon","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib174","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2249.2002.01811.x","article-title":"Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia","volume":"128","author":"Yang","year":"2002","journal-title":"Clin. Exp. Immunol."},{"issue":"206","key":"10.1016\/j.rmed.2018.12.015_bib175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006998","article-title":"BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease","volume":"5","author":"Shum","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib176","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/cei.12636","article-title":"Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosis","volume":"181","author":"Ten Klooster","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib177","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri2322","article-title":"The regulation of IgA class switching","volume":"8","author":"Cerutti","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib178","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1165\/ajrcmb\/5.2.155","article-title":"Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis","volume":"5","author":"Khalil","year":"1991","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib179","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib180","first-page":"779","article-title":"Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters","volume":"125","author":"Iyer","year":"1995","journal-title":"J. Lab. Clin. Med."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib181","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/01902149809046058","article-title":"Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model","volume":"24","author":"Iyer","year":"1998","journal-title":"Exp. Lung Res."},{"issue":"10","key":"10.1016\/j.rmed.2018.12.015_bib182","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1248\/bpb.b13-00452","article-title":"Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis","volume":"36","author":"Togami","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.rmed.2018.12.015_bib183","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts","volume":"58","author":"Conte","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib184","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1023\/A:1007068313370","article-title":"Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation","volume":"24","author":"Iyer","year":"2000","journal-title":"Inflammation"},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib185","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1096\/fj.201600892RR","article-title":"Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors","volume":"31","author":"Didiasova","year":"2017","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib186","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","article-title":"A novel antifibrotic mechanism of nintedanib and pirfenidone. Inhibition of collagen fibril assembly","volume":"57","author":"Knuppel","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib187","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/TP.0b013e3182584879","article-title":"Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection","volume":"94","author":"Bizargity","year":"2012","journal-title":"Transplantation"},{"issue":"1\u20133","key":"10.1016\/j.rmed.2018.12.015_bib188","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2011.12.025","article-title":"Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis","volume":"678","author":"Navarro-Partida","year":"2012","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib189","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/TP.0b013e3181ae3392","article-title":"Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses","volume":"88","author":"Visner","year":"2009","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.kjms.2017.03.011","article-title":"The effects of pirfenidone on T helper cells in prevention of intraperitoneal adhesions","volume":"33","author":"Ozbilgin","year":"2017","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"2","key":"10.1016\/j.rmed.2018.12.015_bib191","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"4\u20135","key":"10.1016\/j.rmed.2018.12.015_bib192","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/01902148.2017.1339141","article-title":"Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model","volume":"43","author":"Lee","year":"2017","journal-title":"Exp. Lung Res."},{"key":"10.1016\/j.rmed.2018.12.015_bib193","doi-asserted-by":"crossref","first-page":"44545","DOI":"10.1038\/srep44545","article-title":"Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model","volume":"7","author":"Ozturk Akcora","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib194","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01209-2017","article-title":"Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years","volume":"50","author":"Raghu","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"22","key":"10.1016\/j.rmed.2018.12.015_bib195","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","article-title":"Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis","volume":"370","author":"Idiopathic Pulmonary Fibrosis Clinical Research","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2018.12.015_bib196","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fmed.2017.00118","article-title":"Exploring animal models that resemble idiopathic pulmonary fibrosis","volume":"4","author":"Tashiro","year":"2017","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib197","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12931-018-0783-2","article-title":"Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation","volume":"19","author":"Kamio","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2018.12.015_bib198","doi-asserted-by":"crossref","first-page":"7934362","DOI":"10.1155\/2018\/7934362","article-title":"TRAIL-dependent resolution of pulmonary fibrosis","volume":"2018","author":"Habiel","year":"2018","journal-title":"Mediat. Inflamm."},{"issue":"11","key":"10.1016\/j.rmed.2018.12.015_bib199","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/thoraxjnl-2016-208423","article-title":"Pulmonary CCR2(+)CD4(+) T cells are immune regulatory and attenuate lung fibrosis development","volume":"72","author":"Milger","year":"2017","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib200","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.ajpath.2010.11.055","article-title":"Gammadelta T cells attenuate bleomycin-induced fibrosis through the production of CXCL10","volume":"178","author":"Pociask","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.rmed.2018.12.015_bib201","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10753-008-9062-6","article-title":"IL-17 producing gammadelta T cells are required for a controlled inflammatory response after bleomycin-induced lung injury","volume":"31","author":"Braun","year":"2008","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib202","doi-asserted-by":"crossref","first-page":"L569","DOI":"10.1152\/ajplung.00565.2016","article-title":"Activated human T lymphocytes inhibit TGFbeta-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2","volume":"314","author":"Lacy","year":"2018","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.rmed.2018.12.015_bib203","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1465-9921-14-73","article-title":"Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials","volume":"14","author":"Collard","year":"2013","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib204","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11739-015-1204-x","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review","volume":"10","author":"Luppi","year":"2015","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.rmed.2018.12.015_bib205","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3389\/fimmu.2017.01756","article-title":"Stimulator of interferon genes deficiency in acute exacerbation of idiopathic pulmonary fibrosis","volume":"8","author":"Qiu","year":"2017","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib206","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.4049\/jimmunol.179.6.4035","article-title":"Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P","volume":"179","author":"Pilling","year":"2007","journal-title":"J. Immunol."},{"issue":"22","key":"10.1016\/j.rmed.2018.12.015_bib207","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1001\/jama.2018.6129","article-title":"Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial","volume":"19","author":"Raghu","year":"2018","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib208","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1164\/rccm.201704-0784OC","article-title":"A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis","volume":"197","author":"Parker","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.12.015_bib209","first-page":"A166","article-title":"The RIFF study (cohort a): a phase II, randomized, double-blind, placebo-controlled trial of lebrikizumab as monotherapy in patients with idiopathic pulmonary fibrosis","volume":"197","author":"Swigris","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.12.015_bib210","first-page":"A6168","article-title":"The RIFF study (cohort B): a phase II, randomized, double-blind, placebo-controlled trial of lebrikizumab in combination with pirfenidone in patients with idiopathic pulmonary fibrosis","author":"Maher","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.12.015_bib211","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01130-2018","article-title":"SAR156597 in idiopathic pulmonary fibrosis: a phase 2, placebo-controlled study (DRI11772)","author":"Raghu","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.015_bib212","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/imm.12215","article-title":"Regulation of pancreatic inflammation by connective tissue growth factor (CTGF\/CCN2)","volume":"141","author":"Charrier","year":"2014","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib213","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1183\/13993003.01030-2015","article-title":"FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis","volume":"47","author":"Raghu","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"Pt 3","key":"10.1016\/j.rmed.2018.12.015_bib214","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1042\/bj2910677","article-title":"The bioactive phospholipid lysophosphatidic acid is released from activated platelets","volume":"291","author":"Eichholtz","year":"1993","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib215","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1165\/rcmb.2012-0004OC","article-title":"Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis","volume":"47","author":"Oikonomou","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"8","key":"10.1016\/j.rmed.2018.12.015_bib216","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2018.12.015_bib217","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","article-title":"Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis","volume":"154","author":"Palmer","year":"2018","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib218","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int. Immunopharm."},{"issue":"6","key":"10.1016\/j.rmed.2018.12.015_bib219","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127771","article-title":"Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Donahoe","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.rmed.2018.12.015_bib220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ni.3069","article-title":"The lungs at the frontlines of immunity","volume":"16","year":"2015","journal-title":"Nat. Immunol."},{"issue":"300","key":"10.1016\/j.rmed.2018.12.015_bib221","doi-asserted-by":"crossref","first-page":"300ps317","DOI":"10.1126\/scitranslmed.aaa9970","article-title":"Precision medicine: beyond the inflection point","volume":"7","author":"Hawgood","year":"2015","journal-title":"Sci. Transl. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119300071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119300071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:47:14Z","timestamp":1760615234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611119300071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":221,"alternative-id":["S0954611119300071"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2018.12.015","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation and immunity in IPF pathogenesis and treatment","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2018.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}